RORA and dry age related macular degeneration: Targeting RORα and its related pathway may thus provide a new way to tackle CNV in late neovascular AMD or even early dry AMD by addressing both angiogenic and inflammatory pathogenic factors, which can offer more advantage than targeting a single pathway.